{"pmid":32492196,"title":"High-Coverage SARS-CoV-2 Genome Sequences Acquired by Target Capture Sequencing.","text":["High-Coverage SARS-CoV-2 Genome Sequences Acquired by Target Capture Sequencing.","In this study, we designed a set of SARS-CoV-2 enrichment probes to increase the capacity for sequence-based virus detection and obtain the comprehensive genome sequence at the same time. This universal SARS-CoV-2 enrichment probe set contains 502 120nt ssDNA biotin-labeled probes designed based on all available SARS-CoV-2 viral sequences and it can be used to enrich for SARS-CoV-2 sequences without prior knowledge of type or subtype. Following the CDC health and safety guidelines, marked enrichment was demonstrated in a virus strain sample from a cell culture, three nasopharyngeal swab samples (cycle threshold [Ct] values: 32.36, 36.72, and 38.44) from patients diagnosed with COVID-19 (positive control) and four throat swab samples from patients without COVID-19 (negative controls), respectively. Moreover, based on these high-quality sequences, we discuss the heterozygosity and viral expression during coronavirus replication, and its phylogenetic relationship with other selected high-quality samples from The Genome Variation Map (GVM). Therefore, this universal SARS-CoV-2 enrichment probe system can capture and enrich SARS-CoV-2 viral sequences selectively and effectively in different samples, especially clinical swab samples with a relatively low concentration of viral particles. This article is protected by copyright. All rights reserved.","J Med Virol","Wen, Shaoqing","Sun, Chang","Zheng, Huanying","Wang, Lingxiang","Zhang, Huan","Zou, Lirong","Liu, Zhe","Du, Panxin","Xu, Xuding","Liang, Lijun","Peng, Xiaofang","Zhang, Wei","Wu, Jie","Yang, Jiyuan","Lei, Bo","Zeng, Guangyi","Ke, Changwen","Chen, Fang","Zhang, Xiao","32492196"],"abstract":["In this study, we designed a set of SARS-CoV-2 enrichment probes to increase the capacity for sequence-based virus detection and obtain the comprehensive genome sequence at the same time. This universal SARS-CoV-2 enrichment probe set contains 502 120nt ssDNA biotin-labeled probes designed based on all available SARS-CoV-2 viral sequences and it can be used to enrich for SARS-CoV-2 sequences without prior knowledge of type or subtype. Following the CDC health and safety guidelines, marked enrichment was demonstrated in a virus strain sample from a cell culture, three nasopharyngeal swab samples (cycle threshold [Ct] values: 32.36, 36.72, and 38.44) from patients diagnosed with COVID-19 (positive control) and four throat swab samples from patients without COVID-19 (negative controls), respectively. Moreover, based on these high-quality sequences, we discuss the heterozygosity and viral expression during coronavirus replication, and its phylogenetic relationship with other selected high-quality samples from The Genome Variation Map (GVM). Therefore, this universal SARS-CoV-2 enrichment probe system can capture and enrich SARS-CoV-2 viral sequences selectively and effectively in different samples, especially clinical swab samples with a relatively low concentration of viral particles. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Wen, Shaoqing","Sun, Chang","Zheng, Huanying","Wang, Lingxiang","Zhang, Huan","Zou, Lirong","Liu, Zhe","Du, Panxin","Xu, Xuding","Liang, Lijun","Peng, Xiaofang","Zhang, Wei","Wu, Jie","Yang, Jiyuan","Lei, Bo","Zeng, Guangyi","Ke, Changwen","Chen, Fang","Zhang, Xiao"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32492196","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26116","keywords":["gene expression","genetic networks","genetic variability","mutation","sars coronavirus"],"locations":["swab"],"topics":["Diagnosis","Mechanism"],"weight":1,"_version_":1668892169244508160,"score":9.490897,"similar":[{"pmid":32501535,"title":"Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","text":["Identification of nsp1 gene as the target of SARS-CoV-2 real-time RT-PCR using nanopore whole genome sequencing.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved.","J Med Virol","Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang","32501535"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the COVID-19 pandemic. Accurate detection of SARS-CoV-2 using molecular assays is critical for patient management and the control of the COVID-19 pandemic. However, there is an increasing number of SARS-CoV-2 viruses with mutations at the primer or probe binding sites, and these mutations may affect the sensitivity of currently available real-time reverse transcription-polymerase chain reaction (RT-PCR) assays targeting the N, E, and ORF1a/b genes. Using sequence-independent single-primer amplification (SISPA) and nanopore whole-genome sequencing, we have found that the nsp1 gene, located at the 5' end of the SARS-CoV-2 genome, was highly expressed in the nasopharyngeal or saliva specimens of 9 COVID-19 patients of different clinical severity. Based on this finding, we have developed a novel nsp1 real-time RT-PCR assay. The primers and probes are highly specific for SARS-CoV-2. Validation with 101 clinical specimens showed that our nsp1 RT-PCR assay has a sensitivity of 93.1% (95% confidence interval, 86.2-97.2%), which was similar to those of N and E gene RT-PCR assays. The diagnostic specificity was 100% (95% CI, 92.9-100%). The addition of nsp1 for multi-target detection of SARS-CoV-2 can avoid false negative results due to mutations at the primers/probes binding sites of currently available RT-PCR assays. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chan, Wan-Mui","Ip, Jonathan Daniel","Chu, Allen Wing-Ho","Yip, Cyril Chik-Yan","Lo, Lap-Sum","Chan, Kwok-Hung","Ng, Anthony Chin-Ki","Poon, Rosana Wing-Shan","To, Wing-Kin","Tsang, Owen Tak-Yin","Leung, Wai-Shing","Kwan, Mike Yat-Wah","Chua, Gilbert T","Chung, Tom Wai-Hin","Hung, Ivan Fan-Ngai","Kok, Kin-Hang","Cheng, Vincent Chi-Chung","Chan, Jasper Fuk-Woo","Yuen, Kwok-Yung","To, Kelvin Kai-Wang"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501535","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26140","keywords":["covid-19","rt-pcr","sars-cov-2","diagnosis","nanopore sequencing","nsp1"],"topics":["Mechanism","Diagnosis"],"weight":1,"_version_":1668890966407249920,"score":298.1602},{"pmid":32167180,"title":"The establishment of reference sequence for SARS-CoV-2 and variation analysis.","text":["The establishment of reference sequence for SARS-CoV-2 and variation analysis.","Starting around December 2019, an epidemic of pneumonia, which was named COVID-19 by the World Health Organization, broke out in Wuhan, China, and is spreading throughout the world. A new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses was soon found to be the cause. At present, the sensitivity of clinical nucleic acid detection is limited, and it is still unclear whether it is related to genetic variation. In this study, we retrieved 95 full-length genomic sequences of SARAS-CoV-2 strains from the National Center for Biotechnology Information and GISAID databases, established the reference sequence by conducting multiple sequence alignment and phylogenetic analyses, and analyzed sequence variations along the SARS-CoV-2 genome. The homology among all viral strains was generally high, among them, 99.99% (99.91%-100%) at the nucleotide level and 99.99% (99.79%-100%) at the amino acid level. Although overall variation in open-reading frame (ORF) regions is low, 13 variation sites in 1a, 1b, S, 3a, M, 8, and N regions were identified, among which positions nt28144 in ORF 8 and nt8782 in ORF 1a showed mutation rate of 30.53% (29/95) and 29.47% (28/95), respectively. These findings suggested that there may be selective mutations in SARS-COV-2, and it is necessary to avoid certain regions when designing primers and probes. Establishment of the reference sequence for SARS-CoV-2 could benefit not only biological study of this virus but also diagnosis, clinical monitoring and intervention of SARS-CoV-2 infection in the future.","J Med Virol","Wang, Changtai","Liu, Zhongping","Chen, Zixiang","Huang, Xin","Xu, Mengyuan","He, Tengfei","Zhang, Zhenhua","32167180"],"abstract":["Starting around December 2019, an epidemic of pneumonia, which was named COVID-19 by the World Health Organization, broke out in Wuhan, China, and is spreading throughout the world. A new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group of the International Committee on Taxonomy of Viruses was soon found to be the cause. At present, the sensitivity of clinical nucleic acid detection is limited, and it is still unclear whether it is related to genetic variation. In this study, we retrieved 95 full-length genomic sequences of SARAS-CoV-2 strains from the National Center for Biotechnology Information and GISAID databases, established the reference sequence by conducting multiple sequence alignment and phylogenetic analyses, and analyzed sequence variations along the SARS-CoV-2 genome. The homology among all viral strains was generally high, among them, 99.99% (99.91%-100%) at the nucleotide level and 99.99% (99.79%-100%) at the amino acid level. Although overall variation in open-reading frame (ORF) regions is low, 13 variation sites in 1a, 1b, S, 3a, M, 8, and N regions were identified, among which positions nt28144 in ORF 8 and nt8782 in ORF 1a showed mutation rate of 30.53% (29/95) and 29.47% (28/95), respectively. These findings suggested that there may be selective mutations in SARS-COV-2, and it is necessary to avoid certain regions when designing primers and probes. Establishment of the reference sequence for SARS-CoV-2 could benefit not only biological study of this virus but also diagnosis, clinical monitoring and intervention of SARS-CoV-2 infection in the future."],"journal":"J Med Virol","authors":["Wang, Changtai","Liu, Zhongping","Chen, Zixiang","Huang, Xin","Xu, Mengyuan","He, Tengfei","Zhang, Zhenhua"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32167180","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.1002/jmv.25762","keywords":["sars-cov-2","homology","nucleotide","reference sequence","variation"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138490640793600,"score":272.13034},{"pmid":32384153,"title":"Rapid detection of SARS-CoV-2 by low volume real-time single tube reverse transcription recombinase polymerase amplification using an exo probe with an internally linked quencher (exo-IQ).","text":["Rapid detection of SARS-CoV-2 by low volume real-time single tube reverse transcription recombinase polymerase amplification using an exo probe with an internally linked quencher (exo-IQ).","BACKGROUND: The current outbreak of SARS-CoV-2 has spread to almost every country with more than three million confirmed cases and over two hundred thousand deaths as of April 28, 2020. Rapid first-line testing protocols are needed for outbreak control and surveillance. METHODS: We used computational and manual design to generate a suitable set of reverse transcription recombinase polymerase amplification (RT-RPA) primer and exonuclease probe, internally quenched (exo-IQ) probe sequences targeting the SARS-CoV-2 N gene. RT-RPA sensitivity was determined by amplification of in vitro transcribed RNA standards. Assay selectivity was demonstrated with a selectivity panel of 32 nucleic acid samples derived from common respiratory viruses. To validate the assay against full-length SARS-CoV-2 RNA, total viral RNA derived from cell culture supernatant and 19 nasopharyngeal swab samples (8 positive and 11 negative for SARS-CoV-2) were screened. All results were compared to established RT-qPCR assays. RESULTS: The 95% detection probability of the RT-RPA assay was determined to be 7.74 (95% CI: 2.87 - 27.39) RNA copies per reaction. The assay showed no cross-reactivity to any other screened coronaviruses or respiratory viruses of clinical significance. The developed RT-RPA assay produced 100% diagnostic sensitivity and specificity when compared to RT-qPCR (n=20). CONCLUSION: With a run time of 15 to 20 minutes and first results being available in under 7 minutes for high RNA concentrations, the reported assay constitutes one of the fastest nucleic acid based detection methods for SARS-CoV-2 to date and may provide a simple to use alternative to RT-qPCR for first-line screening at the point of need.","Clin Chem","Behrmann, Ole","Bachmann, Iris","Spiegel, Martin","Schramm, Marina","El Wahed, Ahmed Abd","Dobler, Gerhard","Dame, Gregory","Hufert, Frank T","32384153"],"abstract":["BACKGROUND: The current outbreak of SARS-CoV-2 has spread to almost every country with more than three million confirmed cases and over two hundred thousand deaths as of April 28, 2020. Rapid first-line testing protocols are needed for outbreak control and surveillance. METHODS: We used computational and manual design to generate a suitable set of reverse transcription recombinase polymerase amplification (RT-RPA) primer and exonuclease probe, internally quenched (exo-IQ) probe sequences targeting the SARS-CoV-2 N gene. RT-RPA sensitivity was determined by amplification of in vitro transcribed RNA standards. Assay selectivity was demonstrated with a selectivity panel of 32 nucleic acid samples derived from common respiratory viruses. To validate the assay against full-length SARS-CoV-2 RNA, total viral RNA derived from cell culture supernatant and 19 nasopharyngeal swab samples (8 positive and 11 negative for SARS-CoV-2) were screened. All results were compared to established RT-qPCR assays. RESULTS: The 95% detection probability of the RT-RPA assay was determined to be 7.74 (95% CI: 2.87 - 27.39) RNA copies per reaction. The assay showed no cross-reactivity to any other screened coronaviruses or respiratory viruses of clinical significance. The developed RT-RPA assay produced 100% diagnostic sensitivity and specificity when compared to RT-qPCR (n=20). CONCLUSION: With a run time of 15 to 20 minutes and first results being available in under 7 minutes for high RNA concentrations, the reported assay constitutes one of the fastest nucleic acid based detection methods for SARS-CoV-2 to date and may provide a simple to use alternative to RT-qPCR for first-line screening at the point of need."],"journal":"Clin Chem","authors":["Behrmann, Ole","Bachmann, Iris","Spiegel, Martin","Schramm, Marina","El Wahed, Ahmed Abd","Dobler, Gerhard","Dame, Gregory","Hufert, Frank T"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32384153","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1093/clinchem/hvaa116","keywords":["amplification","covid-19","poct","point-of-care","rpa","sars-cov-2"],"topics":["Diagnosis"],"weight":1,"_version_":1666419683359719424,"score":266.40356},{"pmid":32425334,"pmcid":"PMC7233248","title":"Sequence mismatch in PCR probes may mask the COVID-19 detection in Nepal.","text":["Sequence mismatch in PCR probes may mask the COVID-19 detection in Nepal.","*Most of the COVID-19 cases in Nepal are in the Southern districts of Nepal bordering India and many cases have travel history to India.*Very few positive cases of COVID-19 are detected in Nepal which could either be due to early national lockdown or inefficiency of PCR methods.*Whole genomes of 93 clinical samples from COVID-19 patients were analysed to find the primer and probe binding sites.*Mutations in probe binding sites were found and this could significantly impact PCR efficiency resulting in false negative results.","Mol Cell Probes","Rana, Divya Rsjb","Pokhrel, Nischal","32425334"],"abstract":["*Most of the COVID-19 cases in Nepal are in the Southern districts of Nepal bordering India and many cases have travel history to India.*Very few positive cases of COVID-19 are detected in Nepal which could either be due to early national lockdown or inefficiency of PCR methods.*Whole genomes of 93 clinical samples from COVID-19 patients were analysed to find the primer and probe binding sites.*Mutations in probe binding sites were found and this could significantly impact PCR efficiency resulting in false negative results."],"journal":"Mol Cell Probes","authors":["Rana, Divya Rsjb","Pokhrel, Nischal"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425334","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.mcp.2020.101599","keywords":["coronavirus disease 2019 (covid-19)","global initiative on sharing of all influenza data (gisaid)","india","mutation","nepal","polymerase chain reaction"],"locations":["Nepal","Southern","Nepal","India","Nepal","Nepal"],"countries":["India","Nepal"],"countries_codes":["IND|India","NPL|Nepal"],"topics":["Diagnosis"],"weight":1,"_version_":1667252837732581376,"score":246.36852},{"pmid":32242873,"title":"Full-genome sequences of the first two SARS-CoV-2 viruses from India.","text":["Full-genome sequences of the first two SARS-CoV-2 viruses from India.","Background & objectives: Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has globally affected 195 countries. In India, suspected cases were screened for SARS-CoV-2 as per the advisory of the Ministry of Health and Family Welfare. The objective of this study was to characterize SARS-CoV-2 sequences from three identified positive cases as on February 29, 2020. Methods: Throat swab/nasal swab specimens for a total of 881 suspected cases were screened by E gene and confirmed by RdRp (1), RdRp (2) and N gene real-time reverse transcription-polymerase chain reactions and next-generation sequencing. Phylogenetic analysis, molecular characterization and prediction of B- and T-cell epitopes for Indian SARS-CoV-2 sequences were undertaken. Results: Three cases with a travel history from Wuhan, China, were confirmed positive for SARS-CoV-2. Almost complete (29,851 nucleotides) genomes of case 1, case 3 and a fragmented genome for case 2 were obtained. The sequences of Indian SARS-CoV-2 though not identical showed high (~99.98%) identity with Wuhan seafood market pneumonia virus (accession number: NC 045512). Phylogenetic analysis showed that the Indian sequences belonged to different clusters. Predicted linear B-cell epitopes were found to be concentrated in the S1 domain of spike protein, and a conformational epitope was identified in the receptor-binding domain. The predicted T-cell epitopes showed broad human leucocyte antigen allele coverage of A and B supertypes predominant in the Indian population. Interpretation & conclusions: The two SARS-CoV-2 sequences obtained from India represent two different introductions into the country. The genetic heterogeneity is as noted globally. The identified B- and T-cell epitopes may be considered suitable for future experiments towards the design of vaccines and diagnostics. Continuous monitoring and analysis of the sequences of new cases from India and the other affected countries would be vital to understand the genetic evolution and rates of substitution of the SARS-CoV-2.","Indian J Med Res","Yadav, Pragya D","Potdar, Varsha A","Choudhary, Manohar Lal","Nyayanit, Dimpal A","Agrawal, Megha","Jadhav, Santosh M","Majumdar, Triparna D","Shete-Aich, Anita","Basu, Atanu","Abraham, Priya","Cherian, Sarah S","32242873"],"abstract":["Background & objectives: Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has globally affected 195 countries. In India, suspected cases were screened for SARS-CoV-2 as per the advisory of the Ministry of Health and Family Welfare. The objective of this study was to characterize SARS-CoV-2 sequences from three identified positive cases as on February 29, 2020. Methods: Throat swab/nasal swab specimens for a total of 881 suspected cases were screened by E gene and confirmed by RdRp (1), RdRp (2) and N gene real-time reverse transcription-polymerase chain reactions and next-generation sequencing. Phylogenetic analysis, molecular characterization and prediction of B- and T-cell epitopes for Indian SARS-CoV-2 sequences were undertaken. Results: Three cases with a travel history from Wuhan, China, were confirmed positive for SARS-CoV-2. Almost complete (29,851 nucleotides) genomes of case 1, case 3 and a fragmented genome for case 2 were obtained. The sequences of Indian SARS-CoV-2 though not identical showed high (~99.98%) identity with Wuhan seafood market pneumonia virus (accession number: NC 045512). Phylogenetic analysis showed that the Indian sequences belonged to different clusters. Predicted linear B-cell epitopes were found to be concentrated in the S1 domain of spike protein, and a conformational epitope was identified in the receptor-binding domain. The predicted T-cell epitopes showed broad human leucocyte antigen allele coverage of A and B supertypes predominant in the Indian population. Interpretation & conclusions: The two SARS-CoV-2 sequences obtained from India represent two different introductions into the country. The genetic heterogeneity is as noted globally. The identified B- and T-cell epitopes may be considered suitable for future experiments towards the design of vaccines and diagnostics. Continuous monitoring and analysis of the sequences of new cases from India and the other affected countries would be vital to understand the genetic evolution and rates of substitution of the SARS-CoV-2."],"journal":"Indian J Med Res","authors":["Yadav, Pragya D","Potdar, Varsha A","Choudhary, Manohar Lal","Nyayanit, Dimpal A","Agrawal, Megha","Jadhav, Santosh M","Majumdar, Triparna D","Shete-Aich, Anita","Basu, Atanu","Abraham, Priya","Cherian, Sarah S"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32242873","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.4103/ijmr.IJMR_663_20","keywords":[" india"," kerala"," genomes"," next-generation sequencing"," phylogeny"," real-time reverse transcription-polymerase chain reaction"," severe acute respiratory syndrome coronavirus 2","epitope"],"locations":["India","Indian","Wuhan","China","Indian","Wuhan","Indian","Indian","India","India","India"],"countries":["India","China"],"countries_codes":["IND|India","CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1666138492153888768,"score":245.05014}]}